EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells

Alexandra von Jutrzenka-Trzebiatowski, Rutuja Gupte iD, Cansu Daglar, Nicole Berndt, Claudia Arndt iD, Michael Bachmann iD, Anja Feldmann

International Journal of Molecular Sciences · 23.05.2025 · 26 (11) · 5024

DOI: 10.3390/ijms26115024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.05.2025. Verfasst von Alexandra von Jutrzenka-Trzebiatowski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328 Dresden, Germany. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry of Education and Research, Saxon State Ministry for Science, Culture and Tourism, Else Kröner-Fresenius-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Reverse Chimeric Antigen Receptor (RevCAR) system is an adapter CAR T cell technology that allows the precise tuning of T cell activity and, thus, improved safety management. RevCAR T cells recognize and eradicate tumor cells via a bispecific adapter molecule, termed the RevCAR Target Module (RevTM). To further reduce the risk of on-target off-tumor toxicities, Dual-RevCAR T cells can be employed. These cells harbor two different RevCAR constructs, with the signaling domain of either CD3zeta or CD28. Therefore, Dual-RevCAR T cells only exert their full function when both RevCAR constructs are triggered simultaneously upon recognition of two different tumor antigens via RevTMs, enabling a precise AND-gate targeting approach and rendering them highly interesting for clinical application. For this purpose, standardized and reproducible clinical-grade cell manufacturing is required, for which the CliniMACS Prodigy can be used. Here, we present that automated processing of RevCAR and Dual-RevCAR T cells via the CliniMACS Prodigy results in potent expansion, strong transduction, and a favorable phenotype for clinical application. Moreover, obtained cell products were highly functional in a strict RevTM-dependent manner for both monospecific and AND-gate targeting, clearly underlining their high potential for clinical application against various tumor entities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesHumansCD28 AntigensCD3 ComplexNeoplasmsReceptors, Antigen, T-CellAntigens, Neoplasm

Stichwörter der Autor:innen

CliniMACS ProdigyRevCAR and Dual-RevCAR systemadapter CAR T cellstumor therapy

Substanzen

Receptors, Chimeric AntigenCD28 AntigensCD3 ComplexReceptors, Antigen, T-CellAntigens, Neoplasm

Autor:innen und Institutionen

  • Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328 Dresden, Germany.
  • Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, 01307 Dresden, Germany.
  • National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a Partnership Between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-R…
  • German Cancer Consortium (DKTK), Partner Site Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

ORCID-Profile: Rutuja Gupte, Claudia Arndt, Michael Bachmann

Förderung

  • Federal Ministry of Education and Research
  • Saxon State Ministry for Science, Culture and Tourism
  • Else Kröner-Fresenius-Stiftung
  • Federal Ministry of Education and Research (BMBF

Zitieren

APA

von Jutrzenka-Trzebiatowski, A., Gupte, R., Daglar, C., Berndt, N., Arndt, C., Bachmann, M., & Feldmann, A. (2025). CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells. International Journal of Molecular Sciences, 26(11), 5024. https://doi.org/10.3390/ijms26115024

Vancouver

von Jutrzenka-Trzebiatowski A, Gupte R, Daglar C, Berndt N, Arndt C, Bachmann M, et al. CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells. International Journal of Molecular Sciences. 2025;26(11):5024. doi:10.3390/ijms26115024

BibTeX
@article{vonJutrzenkaTrzebiatowski2025,
  author = {von Jutrzenka-Trzebiatowski, Alexandra and Gupte, Rutuja and Daglar, Cansu and Berndt, Nicole and Arndt, Claudia and Bachmann, Michael and Feldmann, Anja},
  title = {CliniMACS Prodigy Manufacturing of Switchable, AND-Gate CAR T Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {11},
  pages = {5024},
  doi = {10.3390/ijms26115024}
}
Kostenlos starten →